Cargando...

Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models

BACKGROUND: HER2 is an oncogene, expression of which leads to poor prognosis in 30% of breast cancer patients. Although trastuzumab is apparently an effective therapy against HER2-positive tumors, its systemic toxicity and resistance in the majority of patients restricts its applicability. In this s...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gupta, Parul, Srivastava, Sanjay K
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3412708/
https://ncbi.nlm.nih.gov/pubmed/22824293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1741-7015-10-80
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!